Carl Schmid

Carl Schmid is a prominent advocate in the field of HIV/AIDS research and policy, known for his work with the AIDS Institute, where he emphasizes the importance of accessible treatments for individuals affected by HIV. Recently, he has been in the news for his comments on the newly approved HIV prevention injection, lenacapavir, highlighting its potential to change the landscape of HIV prevention and the moral obligation to provide it to those in need.